HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: Which sample should be used?

Histopathology

Volumn 61, Issue 1, 2012, Pages 134-135

  Perrone, Giuseppe ^a   Amato, Michelina ^a   Callea, Marcella ^a   Rabitti, Carla ^a   Righi, Daniela ^a   Crucitti, Pierfilippo ^a   Coppola, Roberto ^a   Onetti Muda, Andrea ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

CANCER TISSUE; CLINICAL PRACTICE; DISTANT METASTASIS; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ANALYSIS; HUMAN; LETTER; METASTASIS; ONCOGENE; PRIORITY JOURNAL; STOMACH CARCINOMA;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; STOMACH NEOPLASMS;

EID: 84862882707     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04251.x     Document Type: Letter

References (4)

1. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376; 687-697.
2. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52; 797-805.
3. Bozzetti C, Negri FV, Lagrasta CA et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br. J. Cancer 2011; 104; 1372-1376.
4. Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59; 822-831.